Developing β-secretase inhibitors for treatment of Alzheimer's disease

Journal of Neurochemistry

Volumn 120, Issue SUPPL. 1, 2012, Pages 71-83

  Ghosh, Arun K ^a   Brindisi, Margherita ^a   Tang, Jordan ^b  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Alzheimer's disease; BACE 1; beta secretase; drugs; inhibitors; memapsin 2

Indexed keywords

2,3 DIHYDRO 6 METHYLGINKGETIN; 2,3 DIHYDROAMENTOFLAVONE; 4 BENZYLOXYPYRROLIDINE DERIVATIVE; 4 PHENOXYPYRROLIDINE DERIVATIVE; ACYLGUANIDINE DERIVATIVE; AMENTOFLAVONE; AMINOHYDANTOIN DERIVATIVE; AMINOIMIDAZOLE DERIVATIVE; AMINOQUINAZOLINE DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CMT 21166; CTS 21166; GRL 8234; GSK 188909; HYDROXYETHYLAMINE DERIVATIVE; HYDROXYETHYLENE DERIVATIVE; IMIDAZOLIDINONE DERIVATIVE; MACROLACTONE; METHYLAMINE DERIVATIVE; OM 99 2; PHENYLNORSTATINE DERIVATIVE; PIPERAZINONE DERIVATIVE; STATINE DERIVATIVE; TAK 070; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IC 50; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; PROTEASE INHIBITORS; TREATMENT OUTCOME;

ANIMALIA; MUS;

EID: 84655162702     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07476.x     Document Type: Review

References (80)

1. Asai M., Hattori C., Iwata N., et al. (2006) The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J. Neurochem. 96, 533-540.
2. Asso V., Ghilardi E., Bertini S., et al. (2008) α- Naphthylaminopropan-2-ol derivatives as BACE-1 inhibitors. ChemMedChem 3, 1530-1534.
3. Baxter E. W., Conway K. A., Kennis L., et al. (2007) 2-Amino-3,4- dihydroquinazolines as inhibitors of BACE-1 (β-Site APP Cleaving Enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead. J. Med. Chem. 50, 4261-4264. (Pubitemid 47378825)
4. Beswick P., Charrier N., Clarke B., et al. (2008) BACE-1 inhibitors part 3: identification of hydroxyethylamines (HEAs) with nanomolar potency in cells. Bioorg. Med. Chem. Lett. 18, 1022-1026. (Pubitemid 351179343)
5. Björklund C., Oscarson S., Benkestock K., et al. (2010) Design and synthesis of potent and selective BACE-1 inhibitors. J. Med. Chem. 53, 1458-1464.
6. Cai H., Wang Y., McCarthy D., Wen H., Borchelt D. R., Price D. L., and, Wong P. C., (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4, 233-234. (Pubitemid 32194867)
7. Cavalli A., Bolognesi M. L., Capsoni S., et al. (2007) A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew. Chem. Int. Ed. 46, 3689-3692. (Pubitemid 46981250)
8. Chang W. P., Koelsch G., Wong S., et al. (2004) In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J. Neurochem. 89, 1409-1416. (Pubitemid 38802662)
9. Chang W., Huang X., Downs D., Cirrito J., Koelsch G., Holzman D. M., Ghosh A. K., and, Tang J., (2011) β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 25, 775-784.
10. Charrier N., Clarke B., Cutler L., et al. (2008) Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability. J. Med. Chem. 51, 3313-3317. (Pubitemid 351821890)
11. Clarke B., Demont E., Dingwall C., et al. (2008a) BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs). Bioorg. Med. Chem. Lett. 18, 1011-1016. (Pubitemid 351179341)
12. Clarke B., Demont E., Dingwall C., et al. (2008b) BACE-1 inhibitors part 2: identification of hydroxyl ethylamines (HEAs) with reduced peptidic character. Bioorg. Med. Chem. Lett. 18, 1017-1021. (Pubitemid 351179342)
13. Cole D. C., Manas E. S., Stock J. R., et al. (2006) Acylguanidines as small-molecule β-Secretase inhibitors. J. Med. Chem. 49, 6158-6161.
14. Cole D. C., Stock J. R., Chopra R., et al. (2008) Acylguanidine inhibitors of β-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg. Med. Chem. Lett. 18, 1063-1066. (Pubitemid 351179339)
15. Cumming J. N., Le T. X., Babu S., et al. (2008) Rational design of novel, potent piperazinone and imidazolidinone BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 18, 3236-3241. (Pubitemid 351718333)
16. Cumming J., Babu S., Huang Y., et al. (2010) Piperazine sulfonamide BACE-1 inhibitors: design, synthesis, and in vivo characterization. Bioorg. Med. Chem. Lett. 20, 2837-2842.
17. Durham T. B., and, Shepherd T. A., (2006) Progress toward the discovery and development of efficacious BACE inhibitors. Curr. Opin. Drug Discov. Dev. 9, 776-791. (Pubitemid 44759568)
18. Freskos J. N., Fobian Y. M., Benson T. E., et al. (2007a) Design of potent inhibitors of human β-secretase. Part 1. Bioorg. Med. Chem. Lett. 17, 73-77. (Pubitemid 44959985)
19. Freskos J. N., Fobian Y. M., Benson T. E., et al. (2007b) Design of potent inhibitors of human β-secretase. Part 2. Bioorg. Med. Chem. Lett. 17, 78-81. (Pubitemid 44959984)
20. Fukumoto H., Takahashi H., Tarui N., et al. (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J. Neurosci. 30, 11157-11166.
21. Ghosh A. K., (2010) Aspartic acid proteases as therapeutic targets in Methods and Principles in Medicinal Chemistry (, Mannhold R., Kubinyi H., and, Folkers G., eds), Vol. 45, pp. 441-479. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
22. Ghosh A. K., Shin D., Downs D., Koelsch G., Lin X., Ermolieff J., and, Tang J., (2000) Design of potent inhibitors for human brain memapsin 2 (β-secretase). J. Am. Chem. Soc. 122, 3522-3523. (Pubitemid 30211128)
23. Ghosh A. K., Bilcer G., Harwood C., et al. (2001) Structure-based design: potent inhibitors of human brain memapsin 2 (β-secretase). J. Med. Chem. 44, 2865-2868. (Pubitemid 32879115)
24. Ghosh A. K., Devasamudram T., Hong L., DeZutter C., Xu X., Weerasena V., Koelsch G., Bilcer G., and, Tang J., (2005) Structure based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase). Bioorg. Med. Chem. Lett. 15, 15-20. (Pubitemid 39575774)
25. Ghosh A. K., Kumaragurubaran N., Hong L., et al. (2007) Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J. Med. Chem. 50, 2399-2407. (Pubitemid 46799251)
26. Ghosh A. K., Gemma S., and, Tang J., (2008a) Beta-secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 3, 399-408. (Pubitemid 351952491)
27. Ghosh A. K., Kumaragurubaran N., Hong L., et al. (2008b) Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X ray structure, and in vivo evaluation. Bioorg. Med. Chem. Lett. 18, 1031-1036. (Pubitemid 351179350)
28. Hamada Y., Igawa N., Ikari H., et al. (2006) β-Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorg. Med. Chem. Lett. 16, 4354-4359.
29. Hanessian S., i Shao Z., Betschart C., Rondeau J.-M., Neumann U., and, Tintelnot-Blomle M., (2010) Structure-based design and synthesis of novel P2/P3 modified, non-peptidic β-secretase (BACE-1) inhibitors. Bioorg. Med. Chem. Lett. 20, 1924-1927.
30. Hey J. A., Koelsch G., Bilcer G., Jacobs A., Tolar M., Tang J., Ghosh A. K., and, Hsu H. H., (2008) Single Dose Administration of the β-Secretase Inhibitor CTS21166 (ASP1720) Reduces Plasma Aβ40 in Human Subjects. International Conference on Alzheimer's Disease (ICAD), Chicago, IL.
31. Hom R. K., Fang L. Y., Mamo S., et al. (2003) Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human β-Secretase. J. Med. Chem. 46, 1799-1802. (Pubitemid 36532222)
32. Hom R. K., Gailunas A. F., Mamo S., et al. (2004) Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human β-secretase. J. Med. Chem. 47, 158-164. (Pubitemid 38040499)
33. Hong L., Koelsch G., Lin X., Wu S., Terzyan S., Ghosh A. K., Zhang X. C., and, Tang J., (2000) Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290, 150-153.
34. Hsu H. H., (2010) Clinical trials for disease-modifying drugs such as BACE inhibitors, in BACE: Lead Target for Orchestrated Therapy of Allheimer's Disease (, John V., ed.), pp. 197-216. John Wiley & Sons, Hoboken, NJ, USA.
35. Huang W., Lv D., Yu H., et al. (2010) Dual-target-directed 1,3-diphenylurea derivatives: BACE-1 inhibitor and metal chelator against Alzheimer's disease. Bioorg. Med. Chem. 18, 5610-5615.
36. Hussain I., Hawkins J., Harrison D., et al. (2007) Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid β production in vivo. J. Neurochem. 100, 802-809. (Pubitemid 46095629)
37. Iserloh U., Wu Y., Cumming J. N., et al. (2008a) Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 18, 414-417.
38. Iserloh U., Pan J., Stamford A. W., et al. (2008b) Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor. Bioorg. Med. Chem. Lett. 18, 418-422.
39. Jennings L. D., Cole D. C., Stock J. R., et al. (2008) Acylguanidine inhibitors of β-secretase: optimization of the pyrrole ring substituents extending into the S1′ substrate binding pocket. Bioorg. Med. Chem. Lett. 18, 767-771.
40. Kimura T., Shuto D., Hamada Y., et al. (2005) Design and synthesis of highly active Alzheimer's β-secretase (BACE-1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg. Med. Chem. Lett. 15, 211-215. (Pubitemid 39575813)
41. Kimura T., Hamada Y., Stochaj M., et al. (2006) Design and synthesis of potent β-secretase (BACE-1) inhibitors with P1′ carboxylic acid bioisosteres. Bioorg. Med. Chem. Lett. 16, 2380-2386.
42. Koelsch G., (2008) Beta-Secretase Inhibitor CTS-21166 Reduces Plasma Abeta40 in Human Subjects. Keystone Symposium on Alzheimer's Disease. Keystone, Colorado; March 24-28.
43. Kortum S. W., Benson T. E., Bienkowski M. J., et al. (2007) Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE-1. Bioorg. Med. Chem. Lett. 17, 3378-3383. (Pubitemid 46819025)
44. Lerchner A., Machauer R., Betschart C., et al. (2010) Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application. Bioorg. Med. Chem. Lett. 20, 603-607.
45. Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M., and, Ashe K. H., (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
46. Li X., Bo H., Zhang X. C., Hartsuck J. A., and, Tang J., (2010) Predicting memapsin 2 (beta-secretae) hydrolytic activity. Protein Sci. 19, 2175-2185.
47. Lindsley S. R., Moore K. P., Rajapakse H. A., et al. (2007) Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 17, 4057-4061. (Pubitemid 46920916)
48. Luo Y., Bolon B., Kahn S., et al. (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4, 231-232. (Pubitemid 32194866)
49. Maillard M. C., Hom R. K., Benson T. E., et al. (2007) Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human β-Secretase. J. Med. Chem. 50, 776-781. (Pubitemid 46332990)
50. Malamas M. S., Erdei J., Gunawan I., et al. (2009) Aminoimidazoles as potent and selective human β-secretase (BACE1) inhibitors. J. Med. Chem. 52, 6314-6323.
51. Malamas M. S., Erdei J., Gunawan I., et al. (2010) Design and synthesis of 5,5′-disubstituted aminohydantoins as potent and selective human β-secretase (BACE-1) inhibitors. J. Med. Chem. 53, 1146-1158.
52. Meredith J. A., Björklund C., Adolfsson H., et al. (2010) P2′-truncated BACE-1 inhibitors with a novel hydroxethylene-like core. Eur. J. Med. Chem. 45, 542-554.
53. Moka N. Y., Chadwick J., Kellett K. A. B., Hooper N. M., Johnson A. P., and, Fishwick C. W. G., (2009) Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorg. Med. Chem. Lett. 19, 6770-6774.
54. Nantermet P. G., Rajapakse H. A., Stanton M. G., et al. (2009) Evolution of tertiary carbinamine BACE-1 inhibitors: Aβ reduction in rhesus CSF upon oral dosing. ChemMedChem 4, 37-40.
55. Nishitomi K., Sakaguchi G., Horikoshi Y., et al. (2006) BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J. Neurochem. 99, 1555-1563. (Pubitemid 44924233)
56. Ohno M., Sametsky E. A., Younkin L., et al. (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27-33. (Pubitemid 38071826)
57. Rajapakse H. A., Nantermet P. G., Selnick H. G., et al. (2006) Discovery of Oxadiazoyl Tertiary Carbinamine Inhibitors of β-Secretase (BACE-1). J. Med. Chem. 49, 7270-7273. (Pubitemid 44913387)
58. Roberds S. L., Anderson J., Basi G., et al. (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317-1324. (Pubitemid 32600485)
59. Sankaranarayanan S., Price E. A., Wu G., et al. (2008) In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J. Pharmacol. Exp. Ther. 324, 957-969. (Pubitemid 351397853)
60. Sankaranarayanan S., Holahan M. A., Colussi D., et al. (2009) First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J. Pharmacol. Exp. Ther. 328, 131-140.
61. Sasaki H., Miki K., Kinoshita K., et al. (2010) β-Secretase (BACE-1) inhibitory effect of bioflavonoids. Bioorg. Med. Chem. Lett. 20, 4558-4560.
62. Sealy J. M., Truong A. P., Tso L., et al. (2009) Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1′ substituents. Bioorg. Med. Chem. Lett. 19, 6386-6391.
63. Selkoe D. J., and, Schenk D., (2008) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545-584.
64. Stachel S. J., Coburn C. A., Steele T. G., et al. (2004) Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J. Med. Chem. 47, 6447-6450. (Pubitemid 39657304)
65. Stachel S. J., Coburn C. A., Sankaranarayanan S., et al. (2006) Macrocyclic inhibitors of beta-secretase: functional activity in an animal model. J. Med. Chem. 49, 6147-6150. (Pubitemid 44595189)
66. Stanton M. G., Stauffer S. R., Gregro A. R., et al. (2007) Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of betaamyloid. J. Med. Chem. 50, 3431-3433. (Pubitemid 47195452)
67. Stauffer S. R., Stanton M. G., Gregro A. R., et al. (2007) Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind β-secretase in a N-terminal 10s-loop down conformation. Bioorg. Med. Chem. Lett. 17, 1788-1792. (Pubitemid 46274326)
68. Tang J., and, Ghosh A. K., (2010) Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned? Aging 3, 14-16.
69. Truong A. P., Tõth G., Probst G. D., et al. (2010) Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg. Med. Chem. Lett. 20, 6231-6236.
70. Turner R. T., III, Koelsch G., Hong L., Castanheira P., Ermolieff J., Ghosh A. K., and, Tang J., (2001) Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 40, 10001-10006. (Pubitemid 32800106)
71. Turner III.R. T., Hong L., Koelsch G., Ghosh A. K., and, Tang J., (2005) Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). Biochemistry 44, 105-112. (Pubitemid 40095711)
72. Wångsell F., Russo F., Sävmarker J., Rosenquist Å., Samuelsson B., and, Larhed M., (2009) Design and synthsis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic. Bioorg. Med. Chem. Lett. 19, 4711-4714.
73. Wångsell F., Gustafsson K., Kvarnström I., et al. (2010) Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core. Eur. J. Med. Chem. 45, 870-882.
74. Wångsell F., Nordeman P., Sävmarker J., et al. (2011) Investigation of α-phenylnorstatine and α-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors. Bioorg. Med. Chem. 19, 145-155.
75. Westerman M. A., Cooper-Blacketer D., Mariash A., et al. (2002) The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858-1867. (Pubitemid 35386304)
76. Wolfe M. S., (2008) Gamma-secretase inhibition and modulation for Alzheimer's disease. Curr. Alzheimer Res. 5, 158-164. (Pubitemid 351536340)
77. Xu W., Chen G., Zhu W., and, Zuo Z., (2010a) Molecular docking and structure-activity relationship studies on benzothiazole based non-peptidic BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 20, 6203-6207.
78. Xu W., Chen G., Zhu W., and, Zuo Z., (2010b) Identification of a sub-micromolar, non-peptide inhibitor of b-secretase with low neural cytotoxicity through in silico screening. Bioorg. Med. Chem. Lett. 20, 5763-5766.
79. Zhu Y., Xiao K., Ma L., et al. (2009) Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and β-secretase. Bioorg. Med. Chem. 17, 1600-1613.
80. Zhu H., Young M. B., Nantermet P. G., et al. (2010) Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors. Bioorg. Med. Chem. Lett. 20, 1779-1782.